论文部分内容阅读
254-S是一种新的顺铂衍生物,其水溶性高于顺铂近10倍,在动物实验中,254-S抗肿瘤活性高于顺铂,肾毒性较顺铂轻。在Ⅱ期临床试验中254-S单用于宫颈癌,有效率为46.3％,高于顺铂和卡铂;匹莱霉素是博莱霉素的衍生物,其肺毒性较轻。基于用顺铂、异环磷酰胺和博莱霉素联合方案治疗宫颈癌复发有效率为69％的事实,用254-S、异环磷酰胺和匹莱霉素联合方案在动物试验和治疗晚期或复发宫颈癌的临床研究中似很有希望,这个方案显示了比254-S单用或以顺铂为主的联合化疗更好的疗效。
254-S is a new cisplatin derivative whose water solubility is nearly 10 times higher than cisplatin. In animal experiments, 254-S has higher anti-tumor activity than cisplatin and nephrotoxicity than cisplatin. In the phase II clinical trial of 254-S single for cervical cancer, the effective rate was 46.3%, higher than that of cisplatin and carboplatin; pimmycin is a derivative of bleomycin, its lung toxicity is light. Based on the fact that cisplatin, ifosfamide, and bleomycin combination regimen was effective in treating 69% of cervical cancer recurrences, the combination of 254-S, ifosfamide and pimmycin was used in animal trials and in the later or advanced stages of treatment The clinical study of recurrent cervical cancer seems hopeful, and this regimen shows better efficacy than 254-S alone or cisplatin-based combination chemotherapy.